Literature DB >> 25576318

Pregnancy in a Patient With a Malignant Brain Tumor Taking Temozolomide: Case Report and Review of the Literature.

Anna C Evans1, Mary Baron Nelson2, Girish Dhall2.   

Abstract

Temozolomide (TMZ), an alkylating agent used in the treatment of malignant gliomas, is a pregnancy category D medication that is not advised for use in pregnant women. We report the case of a 19-year-old woman with anaplastic oligodendroglioma (high-grade glioma) who became pregnant during maintenance chemotherapy consisting of TMZ 200 mg/m(2) administered 5 days monthly. The TMZ was immediately discontinued after she developed a positive pregnancy test. She delivered a full-term healthy baby boy with no prenatal or perinatal complications. Adolescents and young adults with brain tumors are often sexually active and should receive intensive and repeated anticipatory guidance regarding contraception while receiving chemotherapy. Pediatric oncology nurses are in a unique position to provide this education for patients and ensure that young women have appropriate pregnancy testing prior to chemotherapy administration.
© 2015 by Association of Pediatric Hematology/Oncology Nurses.

Entities:  

Keywords:  adolescents; brain tumor; contraception; pregnancy; temozolomide

Mesh:

Substances:

Year:  2015        PMID: 25576318     DOI: 10.1177/1043454214563414

Source DB:  PubMed          Journal:  J Pediatr Oncol Nurs        ISSN: 1043-4542            Impact factor:   1.636


  2 in total

1.  Artificial Intelligence Algorithm-Based Analysis of Ultrasonic Imaging Features for Diagnosis of Pregnancy Complicated with Brain Tumor.

Authors:  Lin Wu; Donghui Wei; Ning Yang; Hong Lei; Yun Wang
Journal:  J Healthc Eng       Date:  2021-11-25       Impact factor: 2.682

2.  Ethical and therapeutic dilemmas in glioblastoma management during pregnancy: Two case reports and review of the literature.

Authors:  Domenico Policicchio; Artan Doda; Giampiero Muggianu; Giosuè Dipellegrini; Riccardo Boccaletti
Journal:  Surg Neurol Int       Date:  2019-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.